Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults

Growth Hormone and IGF Research

Volumn 18, Issue 6, 2008, Pages 506-516

  Mattsson, Anders ^a   Svensson, Dag ^a   Schuett, Burkhardt ^b   Osterziel, Karl J ^b   Ranke, Michael B ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adults; Atypicality index; Insulin like binding proteins; Insulin like growth factor I; Multivariate regression; Reference regions; Standard deviation score

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CORRELATION ANALYSIS; FEMALE; GERMANY; HUMAN; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGING; BODY MASS INDEX; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; REFERENCE VALUES; REGRESSION ANALYSIS; SEX FACTORS; YOUNG ADULT;

EID: 53449089530     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.04.005     Document Type: Article

References (35)

1. Grimberg A., and Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell Physiol. 183 (2000) 1-9
2. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
3. Elmlinger M.W., Kuhnel W., Weber M.M., and Ranke M.B. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin. Chem. Lab. Med. 42 (2004) 654-664
4. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
5. Zumkeller W., and Westphal M. The IGF/IGFBP system in CNS malignancy. Mol. Pathol. 54 (2001) 227-229
6. Baron-Hay S., Boyle F., Ferrier A., and Scott C. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin. Cancer Res. 10 (2004) 1796-1806
7. Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., and Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 (2004) 1346-1353
8. Lofqvist C., Andersson E., Gelander L., Rosberg S., Hulthen L., Blum W.F., et al. Reference values for insulin-like growth factor-binding protein-3 (IGFBP-3) and the ratio of insulin-like growth factor-I to IGFBP-3 throughout childhood and adolescence. J. Clin. Endocrinol. Metab. 90 (2005) 1420-1427
9. Mitchell H., Dattani M.T., Nanduri V., Hindmarsh P.C., Preece M.A., and Brook C.G. Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency. Arch. Dis. Child 80 (1999) 443-447
10. Morimoto L.M., Newcomb P.A., White E., Bigler J., and Potter J.D. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1394-1401
11. Morimoto L.M., Newcomb P.A., White E., Bigler J., and Potter J.D. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 1204-1211
12. Nystrom F.H., Ohman P.K., Ekman B.A., Osterlund M.K., Karlberg B.E., and Arnqvist H.J. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur. J. Endocrinol. 136 (1997) 165-172
13. Bereket A., Turan S., Omar A., Berber M., Ozen A., Akbenlioglu C., et al. Serum IGF-I and IGFBP-3 levels of Turkish children during childhood and adolescence: establishment of reference ranges with emphasis on puberty. Horm Res. 65 (2006) 96-105
14. Ranke M.B., Osterziel K.J., Schweizer R., Schuett B., Weber K., Robbel P., et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays. Clin. Chem. Lab. Med. 41 (2003) 1329-1334
15. Ranke M.B., Schweizer R., Elmlinger M.W., Weber K., Binder G., Schwarze C.P., et al. Relevance of IGF-I, IGFBP-3,and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm Res. 55 (2001) 115-124
16. Marzullo P., Di Somma C., Pratt K.L., Khosravi J., Diamandis A., Lombardi G., et al. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J. Clin. Endocrinol. Metab. 86 (2001) 3001-3008
17. Clemmons D.R. Clinical utility of measurements of insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab. 2 (2006) 436-446
18. Clemmons D.R. IGF-I assays: current assay methodologies and their limitations. Pituitary 10 (2007) 121-128
19. Clemmons D.R. Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol. Metab. Clin. North Am. 36 (2007) 109-129
20. Paramo C., Fluiters E., de la Fuente J., Andrade A., and Garcia-Mayor R.V. Monitoring of treatment success in patients with acromegaly: the value of serum insulin-like growth factor binding protein-3 and serum leptin measurements in comparison to plasma insulin-like growth factor I determination. Metabolism 50 (2001) 1117-1121
21. Blum W.F., Ranke M.B., Kietzmann K., Gauggel E., Zeisel H.J., and Bierich J.R. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J. Clin. Endocrinol. Metab. 70 (1990) 1292-1298
22. Elmlinger M.W., Wimmer K., Biemer E., Blum W.F., Ranke M.B., and Dannecker G.E. Insulin-like growth factor binding protein 2 is differentially expressed in leukaemic B- and T-cell lines. Growth Regul. 6 (1996) 152-157
23. SAS Procedures Guide, Version 8.02. SAS Institute Inc., Cary, NC, USA, 1999.
24. Gutierrez L.P., Koltowska-Haggstrom M., Jonsson P.J., Mattsson A.F., Svensson D., Westberg B., et al. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiol. Drug Saf. 17 (2008) 90-102
25. Harris E.K., and Boyd J.C. Statistical Basis of Reference Values in Laboratory Medicine (1995), Marcel Dekker Inc., New York
26. Burnett R.W. Accurate estimation of standard deviations for quantitative methods used in clinical chemistry. Clin. Chem. 21 (1975) 1935-1938
27. Albert A., and Harris E.K. Multivariate Interpretation of Clinical Laboratory Data (1987), Marcel Dekker Inc., New York
28. Boyd J.C. Reference regions of two or more dimensions. Clin. Chem. Lab. Med. 42 (2004) 739-746
29. Borofsky N.D., Vogelman J.H., Krajcik R.A., and Orentreich N. Utility of insulin-like growth factor-1 as a biomarker in epidemiologic studies. Clin. Chem. 48 (2002) 2248-2251
30. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 (1998) 563-5646
31. Ma J., Pollak M., Giovannucci E., Chan J.M., Tao Y., Hennekens C., et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3,and colorectal cancer risk among men. Growth Horm. IGF Res. 10 Suppl. A (2000) S28-S29
32. Hankinson S.E., Willett W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 (1998) 1393-1396
33. Wolk A., Mantzoros C.S., Andersson S.O., Bergstrom R., Signorello L.B., Lagiou P., et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J. Natl. Cancer Inst. 90 (1998) 911-915
34. Ranke M.B., Maier K.P., Schweizer R., Stadler B., Schleicher S., Elmlinger M.W., et al. Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res. 60 (2003) 174-180
35. Crawley M.J. The R Book (2007), John Wiley & Sons, London